No black box warning on record for Dabigatran

As of the latest FDA labeling reviewed, Dabigatran (Dabigatran etexilate) does not carry a black box warning. Standard warnings and precautions still apply — see the full Dabigatran medicine page for the complete safety profile.

Other warnings & precautions

Premature discontinuation increases risk of stroke — do not stop without medical guidance
Serious and potentially fatal bleeding can occur; no routine reversal agent was available until idarucizumab (Praxbind) approval
Avoid use in patients with mechanical prosthetic heart valves due to increased thromboembolic and bleeding risk
Use with caution or avoid in severe renal impairment (CrCl < 15 mL/min); dose adjustment required for moderate renal impairment
Spinal/epidural hematoma risk with neuraxial anesthesia or spinal puncture — monitor neurological signs
Capsules must be swallowed whole; do not crush, chew, or open capsules
Drug interactions with P-glycoprotein (P-gp) inducers and inhibitors can significantly alter drug exposure
Use caution in elderly patients due to increased bleeding risk and possible renal impairment
Co-administration with other anticoagulants, antiplatelet agents, or NSAIDs increases bleeding risk
Idarucizumab (Praxbind) is the specific reversal agent for dabigatran in emergency situations

No black box warning on record for Dabigatran

Other warnings & precautions

Premature discontinuation increases risk of stroke — do not stop without medical guidance
Serious and potentially fatal bleeding can occur; no routine reversal agent was available until idarucizumab (Praxbind) approval
Avoid use in patients with mechanical prosthetic heart valves due to increased thromboembolic and bleeding risk
Use with caution or avoid in severe renal impairment (CrCl < 15 mL/min); dose adjustment required for moderate renal impairment
Spinal/epidural hematoma risk with neuraxial anesthesia or spinal puncture — monitor neurological signs
Capsules must be swallowed whole; do not crush, chew, or open capsules
Drug interactions with P-glycoprotein (P-gp) inducers and inhibitors can significantly alter drug exposure
Use caution in elderly patients due to increased bleeding risk and possible renal impairment
Co-administration with other anticoagulants, antiplatelet agents, or NSAIDs increases bleeding risk
Idarucizumab (Praxbind) is the specific reversal agent for dabigatran in emergency situations

Dabigatran Black Box Warning

No black box warning on record for Dabigatran

Other warnings & precautions

Dabigatran Black Box Warning

No black box warning on record for Dabigatran

Other warnings & precautions